The FDA has given the go-ahead to the Serum Institute of India (SII) to eventually supply a COVID-19 vaccine to the U.S. with Novavax’s Nuvaxovid. The emergency use authorization granted to Novavax’s recombinant protein-based vaccination on July 13th means SII will be able to distribute the shot, also known as Covovax, to the United States […]

The post Serum Institute Wins USFDA Approval To Export Novavax Jab first appeared on World Pharma Today.